Epstein–Barr virus infection and malignancy in solid organ transplant recipients: strategies for prevention and treatment
- 1 June 2001
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 3 (2) , 56-59
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Anti‐B cell and anti‐cytokine therapy for the treatment of post‐transplant lymphoproliferative disorder: past, present, and futureTransplant Infectious Disease, 2001
- Interferon and cytotoxic chemotherapy for the treatment of post‐transplant lymphoproliferative disorderTransplant Infectious Disease, 2001
- The Epstein–Barr virus and post‐transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesisTransplant Infectious Disease, 2001
- Identifying the patient at risk for post‐transplant lymphoproliferative disorderTransplant Infectious Disease, 2001
- Epstein–Barr virus load monitoring: its role in the prevention and management of post‐transplant lymphoproliferative diseaseTransplant Infectious Disease, 2001
- The diverse pathology of post‐transplant lymphoproliferative disorders: the importance of a standardized approachTransplant Infectious Disease, 2001
- The role of antiviral and immunoglobulin therapy in the prevention of Epstein–Barr virus infection and post‐transplant lymphoproliferative disease following solid organ transplantationTransplant Infectious Disease, 2001
- Value of Long-Term Administration of Acyclovir and Similar Agents for Protecting Against AIDS-Related Lymphoma: Case-Control and Historical Cohort StudiesClinical Infectious Diseases, 2000
- Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patientsAnnals of Oncology, 2000
- Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantationThe Lancet, 1999